

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |      |   |  |
|--|------|---|--|
| Substitute for form 1449B/PTO<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(use as many sheets as necessary) |      | <b>Complete if Known</b><br>Application Number 10/025,222<br>Filing Date 12/19/2001<br>First Named Inventor Pelletier et al.<br>Group Art Unit 1645/652<br>Examiner Name Unassigned<br>Attorney Docket Number 073406-0701 |  |
| 1  | of 8 | RECEIVED<br>DEC 26 2002<br>TECH CENTER 1600/2900  |  |

| U.S. PATENT DOCUMENTS |                       |                      |                                   |   |  |   |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | U.S. Patent Document |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|                       |                       | Number               | Kind Code <sup>2</sup> (if known) |   |  |   |
| DS                    | A1                    | 4,946,968            |                                   | Krimmer et al.                                  | Aug. 7, 1990                                     |   |
|                       | A2                    | 60/110,992           |                                   | U.S. Provisional Patent App.                    | Dec. 5, 1998                                     |   |
|                       | A3                    | 09/075,519           |                                   | U.S. CIP Patent App.                            | Sep. 28, 2000                                    |   |
|                       |                       |                      |                                   |   |  |   |
|                       |                       |                      |                                   |   |  |   |

| FOREIGN PATENT DOCUMENTS |                       |                         |                     |                                      |  |   |   |                |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|--|---|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                      | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>6</sup> |
|                          |                       | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>5</sup><br>(if known) |  |   |   |                |
| DS                       | A4                    |                         | WO 00/32825         | —                                    | Phagotech, Inc.                                  | June 8, 2000  |   |                |
|                          |                       |                         |                     |                                      |  |   |   |                |
|                          |                       |                         |                     |                                      |  |   |   |                |
|                          |                       |                         |                     |                                      |  |   |   |                |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---|-----------------------|--|----------------|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
| DS  | A5                    | ALONSO et al., "Functional analysis of the <i>dna</i> (ts) mutants of <i>Bacillus Subtilis</i> : Plasmid pUB110 replication as a model system," Mol. Gen. Genet, 214:482-489, 1988.  |                |
|   | A6                    | BENKOVIC et al., "Replisome-Mediated DNA Replication," Ann. Rev. Biochem., 70:181-208, 2001.   |                |
|   | A7                    | BENVENISTY et al., "Direct introduction of genes into rats and expression of the genes," Proc. Natl. Acad. Sci. USA, 83:9551-9555, 1986.   |                |
|   | A8                    | BIRD et al., "Mapping Protein-Protein Interactions within a Stable Complex of DNA Primase and DnaB Helicase from <i>Bacillus stearothermophilus</i> ," Biochemistry, 39:171-182, 2000.   |                |
| DN  | A9                    | CHEE et al., "Assessing Genetic Information with High-Density DNA Arrays," Science, 274:610-614, 1996.   |                |

|                    |  |                 |          |
|--------------------|--|-----------------|----------|
| Examiner Signature |  | Date Considered | 12-23-03 |
|--------------------|--|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

2 of 8

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/025,222       |
| Filing Date            | 12/19/2001       |
| First Named Inventor   | Pelletier et al. |
| Group Art Unit         | 1645 / 652       |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | 073406-0701      |

RECEIVED

DEC 26 2002

CH. ENTER 1600/2900

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
| DS                 | A10                   | CLACKSON et al., "Making antibody fragments using phage display libraries," Nature, 352:624-628, 1991.   |                |
|                    | A11                   | COLE et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <u>Monoclonal Antibodies and Cancer Therapy</u> , Proceedings of the Roche-UCLA Symposium held in Park City, Utah, 77-96, 1985.   |                |
|                    | A12                   | COTTON et al., "Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations," Proc. Nat. Acad. Sci. USA, 85:4397-4401, 1955.                                       |                |
|                    | A13                   | CREIGHTON, <u>Proteins: Structures and Molecular Properties</u> , New York: Freeman and Company, 1993, p. 78-99.   |                |
|                    | A14                   | <u>Current Protocols in Immunology</u> , edited by John Coligan, Vol. 1, Chapter 5, New York: John Wiley & Sons, 1991  |                |
|                    | A15                   | DREWS et al., "Drug Discovery: A Historical Perspective," Science, 287:1960-1964, 2000.  |                |
|                    | A16                   | EISENBRAUN et al., "Examination of Parameter: Affecting the Elicitation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic Immunization," DNA and Cell Biology, 12:791-797, 1993.  |                |
|                    | A17                   | FROHMAN et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," Proc. Nat. Acad. Sci. USA, 85:8998-9002, 1988.   |                |
|                    | A18                   | GENTZ et al., "Bioassay for trans-activation using purified human immunodeficiency virus <i>tat</i> -encoded protein: Trans-activation requires mRNA synthesis," Proc. Nat. Acad. Sci. USA, 86:821-824, 1989.  |                |
| DS                 | A19                   | HAARD et al., "A Large Non-immunized human fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies," Journal Biological Chemistry, 274: 18218-18230, 1999.  |                |

Examiner  
Signature

*[Signature]*

Date  
Considered

12-23-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

|   |   |                          |                  |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |   | <b>Compleat if Known</b> |                  |
|   |   | Application Number       | 10/025,222       |
|   |   | Filing Date              | 12/19/2001       |
|   |   | First Named Inventor     | Pelletier et al. |
|   |   | Group Art Unit           | 1645/1652        |
|   |   | Examiner Name            | Unassigned       |
|   |   | Attorney Docket Number   | 073406-0701      |
| Use as many sheets as necessary   | 3 | of                       | 8                |

RECEIVED  
DEC 26 2002  
TECHNICAL CENTER 1600/2002

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---|-----------------------|--|----------------|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
| DIS   | A20                   | HARBARTH et al., "Impact of Methicillin Resistance on the Outcome of Patients with Bacteremia Caused by <i>Staphylococcus aureus</i> ," Arch. Intern. Med., 158:182-189, 1998.   |                |
|   | A21                   | HENIKOFF et al., "Amino acid substitution matrices from protein blocks," Proc. Nat. Acad. Sci. USA, 89: 10915-10919, 1992.   |                |
|   | A22                   | HIGGS et al., "Fluorometric Assay for DNA Polymerases and Reverse Transcriptase," BioTechniques, 21:644-672, 1996.   |                |
|   | A23                   | JONES et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 321: 522-525, 1986.   |                |
|   | A24                   | KAELIN et al., "Expression Cloning of a cDNA Encoding A Retinoblastoma-Binding Protein with E2F-like Properties," Cell, 70:351-364, 1992.  |                |
|   | A25                   | KANEDA et al., "Increased expression of DNA cointroduced with nuclear protein in adult rat liver," Science, 243:375-378, 1989.   |                |
|   | A26                   | KOHLER et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 256: 495-497, 1975.  |                |
| DIS   | A27                   | KORNBERG et al., "Prokaryotic DNA Polymerases Other Than E.coli Pol 1, Chapter 5, <u>DNA Replication</u> , 2 <sup>nd</sup> edition, New York: Freeman and Company, 1992.   |                |



|                    |   |                 |          |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 12-23-03 |
|--------------------|---|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |                        |                    |   |
|--|---|------------------------|--------------------|---|
|  | Substitute for form 1449B/PTO                 |                        | Complete if Known  |   |
|  | INFORMATION DISCLOSURE STATEMENT BY APPLICANT |                        | Application Number | 10/025,222  |
| Use as many sheets as necessary)   |   | Filing Date            | 12/19/2001         |  |
| 4 of 8   |   | First Named Inventor   | Pelletier et al.   |   |
|  |   | Group Art Unit         | 1845 76.52         |   |
|  |   | Examiner Name          | Unassigned         |   |
|  |   | Attorney Docket Number | 073406-0701        |   |

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|-----------------------|--|----------------|
| DS                 | A28                   | KOZBOR et al., "The production of monoclonal antibodies from human lymphocytes," Immunology Today, Vol. 4, No. 3, 72-79, 1983.   |                |
|                    | A29                   | KREISWIRTH et al., "The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage," Nature, 305: 709-712, 1983.  |                |
|                    | A30                   | LADNER, "Display and Selection of Proteins on Genetic Packages," Chapter 10, <u>Phage Display of Peptides and Proteins</u> , 151-193, 1996.  |                |
|                    | A31                   | LAEMMLI, "Cleavage of Structural Proteins during the assembly of the head of bacteriophage T4," Nature, 227: 680-685, 1970.  |                |
|                    | A32                   | LU et al., "Direct physical interaction between DnaG primase and DnaB helicase of <i>Escherichia coli</i> is necessary for optimal synthesis of primer RNA," Proc. Nat. Acad. Sci. USA, 93:12902-12907, 1996.  |                |
|                    | A33                   | MAEJI et al., "Systematic screening for bioactive peptides," Peptide Research, Vol. 4, No. 3, 142-146, 1991.   |                |
| DS                 | A34                   | MANTHORPE et al., "Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice," Human Gene Therapy, Vol. 4, 419-431, 1993.  |                |
|                    | A35                   | MARKS et al., "By-passing immunization: Building high affinity human antibodies by chain shuffling," Bio technology, 10:777-783, 1992.   |                |

|                    |   |                 |          |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 12-23-03 |
|--------------------|---|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.




Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

5 of 8

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/025,222       |
| Filing Date            | 12/19/2001       |
| First Named Inventor   | Pelletier et al. |
| Group Art Unit         | 1645/652         |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | 073406-0701      |



**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
| US                 | A36                   | McCAFFERTY et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>NATURE</i> 348: 552-554 (1996)   |                |
|                    | A37                   | MYERS et al., "Detection of single base substitutions by Ribonuclease cleavage at mismatches in RNA:DNA duplexes, Science, 230:1242-1246, 1985.  |                |
|                    | A38                   | NEEDLEMAN et al., "A General method applicable to the search for similarities in the amino acid sequence of two proteins," J. Mol. Biol., 48:433-453, 1970.  |                |
|                    | A39                   | OKANO et al., "Myelin base protein gene and the function of antisense RNA in its repression in myelin-deficient mutant mouse," Journal of Neurochemistry, 56: 560-567, 1991.   |                |
|                    | A40                   | OSKOUIAN et al., "Repression and catabolite repression of the lactose operon of <i>Staphylococcus aureus</i> ," Journal of Bacteriology, 172: 3804-3812, 1990.   |                |
|                    | A41                   | QIN et al., "A Strategy for rapid, high-confidence protein identification," Annal. Chem., 69:3995-4001, 1997.  |                |
|                    | A42                   | RATTAN et al., "Protein synthesis, posttranslational modifications, and aging," An. N.Y. Acad. Of Sci., 663: 48-62, 1992.  |                |
| US                 | A43                   | RODER et al., "Clinical features of <i>Staphylococcus aureus</i> endocarditis," Arch. Int. Med., 159:462-469, 1999.  |                |


|                    |  |                 |          |
|--------------------|--|-----------------|----------|
| Examiner Signature |  | Date Considered | 12-23-03 |
|--------------------|--|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


6

of

8

Compleat If Known

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/025,222       |
| Filing Date            | 12/19/2001       |
| First Named Inventor   | Pelletier et al. |
| Group Art Unit         | 1645/632         |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | 073406-0701      |



## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
| D/S                | A44                   | ROWEN et al., "Primase, the <i>dnaG</i> Protein of <i>Escherichia coli</i> ," Journal of Biological Chemistry, 253: 758-64, 1978.  |                |
|                    | A45                   | SEEGER et al., "The cloned genome of ground squirrel hepatitis virus is infectious in the animal," Proc. Natl. Acad. Sci. USA, 81: 5849-5852, 1984.  |                |
|                    | A46                   | SEIFTER et al., "Analysis for protein modifications and nonprotein cofactors," Meth. Enzymol., 182: 626-646, 1990.   |                |
|                    | A47                   | SITTAMPALAM et al., "high-throughput screening: advances in assay technologies," Current Opin. Chem. Biol., 3:384-391, 1997.   |                |
|                    | A48                   | SMITH et al., "Identification of common molecular subsequences," J. Mol. Biol., 147: 195-197, 1981.  |                |
|                    | A49                   | SWANSTROM et al., "Agar layer method for production of high titer phage stocks," Proc. Soc. Expt. Biol. Med., 372-375, 1951.   |                |
| D/S                | A50                   | TANG et al., "Genetic immunization in a simple method for eliciting an immune response," Nature, 356: 152-154, 1992.   |                |
|                    | A51                   | TAURIANEN et al., "Recombinant luminescent bacteria for measuring bioavailable arsenite and antimonite," Appl. Environ. Microbiol., 63: 4456-4461, 1997.   |                |

Examiner  
Signature

Date  
Considered


12-23-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

7 of 8

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/025,222       |
| Filing Date            | 12/19/2001       |
| First Named Inventor   | Pelletier et al. |
| Group Art Unit         | 1645/1652        |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | 073406-0701      |



**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
| D/S                | A52                   | TEMPEST et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," Biotechnology, 9: 266-273, 1991.   |                |
|                    | A53                   | TOUGU et al., "Identification of a domain of Escherichia coli primase required for functional interaction with the DnaB helicase at the replication fork," J. Biol. Chem., 269:4675-4682, 1994.  |                |
|                    | A54                   | TONGU et al., "The Interaction between Helicase and Primase sets the replication fork clock," J. Biol. Chem., 271: 21398-21405, 1996.  |                |
|                    | A55                   | WILSON et al., "The structure of an antigenic determinant in a protein," Cell, 37:767-778, 1984.   |                |
|                    | A56                   | WOLD, "Posttranslational protein modifications: perspectives and prospectives," <u>Posttranslational Covalent Modification of Proteins</u> , New York: Academic Press, 1983.   |                |
|                    | A57                   | WOLFF et al., "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle," Human Mol. Genet., 1:363-369, 1992.  |                |
|                    | A58                   | WU et al., "Coordinated leading- and lagging-strand synthesis at the Escherichia coli DNA replication fork," J. Biol. Chem., 267: 4074-4083, 1992.   |                |
| D/S                | A59                   | WU et al., "Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements <i>in Vivo</i> ," J. Biol. Chem., 264: 16985-16987, 1989.  |                |


|                    |  |                 |          |
|--------------------|--|-----------------|----------|
| Examiner Signature |  | Date Considered | 12-23-03 |
|--------------------|--|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |  |                               |                             |                  |
|--|--|-------------------------------|-----------------------------|------------------|
|  | Substitute for form 1449B/PTO                        |                               | <b>Complete if Known</b>    |                  |
|  | <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> |                               | <b>Application Number</b>   | 10/025,222       |
|  |  |                               | <b>Filing Dat</b>           | 12/19/2001       |
|  |  |                               | <b>First Named Inventor</b> | Pelletier et al. |
|  |  |                               | <b>Group Art Unit</b>       | 1645/652         |
|  |  |                               | <b>Examiner Name</b>        | Unassigned       |
| (use as many sheets as necessary)  |  | <b>Attorney Docket Number</b> | 073406-0701                 |                  |
| 8  | of   | 8                             |                             |                  |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---|-----------------------|--|----------------|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
| DS  | A60                   | YUZHAKOV et al., "Trading Places on DNA -- A Three-Point Switch Underlies Primer Handoff from Primase to the Replicative DNA Polymerase," Cell, 96: 153-163, 1999.   |                |
|   |                       |  |                |

RECEIVED  
DEC 26 2002  
TECH CENTER 1600/2300

|                    |   |                 |          |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 12-23-03 |
|--------------------|---|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.





persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for Form ~~AT-40B~~ PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Date Submitted: July 3, 2003**

*(use as many sheets as necessary)*

**C mplete if Known**

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10/025,222          |
| Filing Date            | 12/19/2001          |
| First Name of Inventor | INVENTOR1 FULL NAME |
| Group Art Unit         | 1645/1652           |
| Examiner Name          | Unassigned          |
| Attorney Docket Number | 073406-0701         |

|       |   |    |   |
|-------|---|----|---|
| Sheet | 2 | of | 2 |
|-------|---|----|---|

## NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner  
Signature**

Date  
Considered

12-23-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.**